NCT04274413

Brief Summary

The main causes of acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) in children are defects in genes that have been associated to pancreatitis. Among these gene defects CFTR gene mutations are commonly found, 34% ARP and 23% CP . Since not every CFTR gene mutations clinically manifest, just identifying these CFTR gene mutations may not help to establish a clear role of this defect in the etiology of the individual ARP/CP. The novel beta-adrenergic sweat secretion test is a very sensitive test to detect small abnormalities in CFTR function in form of a linear gene-function relation. By identifying even mild CFTR defects, in future will help in finding the role of CFTR modulators and providing treatment to these patients.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2021

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 16, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 18, 2020

Completed
12 months until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2021

Completed
Last Updated

July 16, 2021

Status Verified

July 1, 2021

Enrollment Period

Same day

First QC Date

February 16, 2020

Last Update Submit

July 12, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessment of CFTR function using the Beta Adrenergic Sweat Secretion Test

    CFTR function assessment of patients with acute recurrent or chronic pancreatitis by using Beta adrenergic sweat test.

    60 mins

Study Arms (1)

Interventional Arm

EXPERIMENTAL

All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.

Combination Product: Beta Adrenergic Sweat Test

Interventions

Beta Adrenergic Sweat TestCOMBINATION_PRODUCT

In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab. 1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site. 2. Under the first probe, injection atropine will be given in one small area of the skin. 3. Under the second probe, first injection carbachol will be given in one small area of the skin. 4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine. 5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded.

Interventional Arm

Eligibility Criteria

Age4 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Age : 4 years and older
  • Diagnosis: Acute recurrent pancreatitis or chronic pancreatitis
  • History: at least one of the following:
  • Carry one or two CFTR mutations
  • Borderline sweat chloride levels
  • Has Family History of CF
  • Has had positive CF Newborn screening

You may not qualify if:

  • Pregnant females: will be excluded at screening.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: Evaporimeter TEWL probes, model RG-1
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor and Senior Associate Scientist

Study Record Dates

First Submitted

February 16, 2020

First Posted

February 18, 2020

Study Start

February 1, 2021

Primary Completion

February 1, 2021

Study Completion

February 1, 2021

Last Updated

July 16, 2021

Record last verified: 2021-07